

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 8 th October 2020 8:15am – 9:30am
Venue	Webex
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes

Attendance	Mr P O'Brien, Deputy Chief Pharmacist (until 9.10am) Dr S Raise, GP ER CCG Mr K McCorry, Medicines Optimisation Pharmacist, NECS Dr B Ali, GP Hull CCG Ms J Morgan, Professional Secretary, Principal Pharmacist – Formulary Prof M Lind, Vice Chair, Professor of Oncology Dr A Sampson, Consultant Infectious Diseases (until 9am) Dr O Ogunbambi, Consultant Rheumatologist Mr A Dawood, Consultant Anaesthetist
Apologies	Mr R Kapur, Vascular Surgeon, HUTH Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr H Klonin, Consultant Paediatrician

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2020.10.01	Apologies	As above					10.20
2020.10.02	Declarations of Interest	None this month					
2020.10.03	Minutes of the previous meeting	KMc ask about Glycopyrronium liquid which was approved for use in paediatric patients with sialhorrea but minutes also refer to adult neurology patients. JM explained that generally botulinum toxin was found to work better in adults and that the new neurology pharmacist once in post would be working on a trust guideline for this cohort to demonstrate when to use botulinum toxin and when to use other pharmacological measure including Glycopyrronium	Noted	WH to amend minutes		10.20	
2020.10.04	Action Tracker	<p>New Product Requests POB to speak to Mr Vize re Dupilumab this has been passed onto AR and POB will chase and feedback next time</p> <p>New Product Requests WH added Glycopyrronium liquid to HERPC agenda</p> <p>New Product Requests AM has written to applicants and WH has updated formulary</p> <p>NICE Guidance JM has requested ARIA forms for TA 638 and TA639 and they are on agenda for discussion</p> <p>MHRA DSU JM has added raising and escalating safety information to the annual report which she has written for presentation at OQC. AM thanked JM for all the work she had put into the writing the report.</p> <p>Fremanezumab Guideline</p>	<p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>POB</p> <p>WH</p> <p>AM</p> <p>JM</p> <p>JM</p>	<p>9.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p>	

		<p>WH added to HERPC agenda</p> <p>Chairs Approval JM contacted Dr Harley for update on Susacs patient who received Rituximab via chairs approval. The patient received both doses and has an appointment with Professor Ahmed next week.</p> <p>AOB WH arranged for everyone to be able to access WEBEX earlier</p>	Action complete	No further action	WH		10.20
			Action complete	No further action	JM		10.20
			Action complete	No further action	WH		10.20
2020.10.05	New Product Requests	<p>New Product Requests Tropicamide/Phenylephrine/Lidocaine (Mydrane) – Mydriasis & Intraocular anaesthesia – Mr Vize This product has been requested to use a small proportion of cataract surgery patients (100 patients) with very small pupils or on alpha blockers who do not respond to standard pre-operative eye drops. Currently ophthalmology are using phenylephrine minims and balanced salt solution off licence for this procedure as an intracameral injection in this patient group. Mydrane is a licensed product and licensed for use in cataract surgery. Patients with small pupils have been shown to respond in the evidence presented.</p> <p>Trametinib – Low Grade Ovarian Cancer – Dr G Bozas Trametinib is on Covid CDF list for this indication, one patient has already received via chairs approval but there is another potential patient. CDF states patients must have failed to respond to platinum based therapy before receiving monotherapy with trametinib. No review was done of this product as it is on Covid CDF however Professor Patmore has given his approval for use.</p> <p>ARIA FORMS</p> <ul style="list-style-type: none"> • TA 638 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer • TA 639 Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer • TA628 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer 	Approved	AM to write to applicants and WH to update formulary	AM/WH	11.20	
			Approved				
			All approved				

		<ul style="list-style-type: none"> TA 642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma 					
2020.10.06	NICE Guidance	<p>August 2020</p> <ul style="list-style-type: none"> TA640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma TA 642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia TA 643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA 644 Entrectinib for treating NTRK fusion-positive solid tumours NG174 COVID-19 rapid guideline: children and young people who are immunocompromised NG 160 COVID-19 rapid guideline: dialysis service delivery NG180 Perioperative care in adults NG181 Rehabilitation for adults with complex psychosis NG 125 Surgical site infections: prevention and treatment NG172 COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response NG178 COVID 19 rapid guideline: renal transplantation CG 134 Anaphylaxis: assessment and referral after emergency treatment <p>September 2020</p> <ul style="list-style-type: none"> TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma 	<p>On formulary</p> <p>On formulary</p> <p>Aria form received</p> <p>JM will chase ARIA form</p> <p>Service specific</p> <p>Service specific</p> <p>No drugs mentioned</p> <p>not for HUTH</p> <p>Noted</p> <p>Service Specific</p> <p>Service Specific</p> <p>Noted</p> <p>ARIA form received and on agenda for discussion</p>	<p>No further action</p> <p>No further action</p> <p>JM to chase form</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	JM	11.20	<p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p>

		<ul style="list-style-type: none"> • TA646 Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) • TA647 Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) • TA648 Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) • NG182 Insect bites and stings: antimicrobial prescribing • CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings • NG12 Suspected cancer: recognition and referral • TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma • TA650 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (Not Recommended) • TA651 Naldemedine for treating opioid-induced constipation – not on formulary. Current agents for this condition are methylnaltrexone and naloxegol and are specialist led. HERPC have guideline for constipation JM to look into if trust require one 	<p>On formulary for another TA On formulary for another TA On formulary for another TA</p> <p>New guideline but no new drugs</p> <p>Update</p> <p>Update</p> <p>JM to request ARIA form</p> <p>On formulary for another TA</p> <p>JM to request application and look into trust guideline</p>				<p>10.20</p> <p>10.20</p> <p>10.20</p> <p>10.20</p> <p>11.20</p> <p>11.20</p>
2020.10.07	MHRA Drug Safety Update	<p>August 2020 Stimulant laxatives available over the counter – new measures to support safe use Clozapine measuring blood concentration for toxicity – JM is looking at writing a trust guideline to include what to do if a patient wishes to stop smoking or if a patient is admitted and has missed a dose. Denosumab 60mg (Prolia) increased risk of vertebral fracture if after stopping or delaying ongoing treatment Baricitinib increased risk of diverticulitis Isotretinoin reminder of important risks and precautions</p> <p>September 2020</p>	Noted				

		<p>Opiate risks of dependence and addiction Transdermal Fentanyl patches for use in non cancer pain;Do not use in opioid naïve patients. The committee felt this would be more of a problem in primary care and KMc agreed to circulate via Hot Topics.</p> <p>The committee wished to discuss this in more depth and requested it be added to next month's agenda. Principal Pharmacist for surgery will also be raising at surgery governance.</p> <p>Methotrexate once weekly for autoimmune disease new measures to reduce risk of fatal overdose use still not being adhered to</p> <p>Insulin and risk of cutaneous amyloidosis at injection site.</p> <p>NPSA Steroid Emergency Alert Card Action required by 13th May 2021. Alert recommends card should be given at point of prescribing. The trust has appointed Dr Purva as the executive lead but the pharmacy department will be doing most of the work.</p> <p>JM informed the committee that the LPC had sent information out to community pharmacies including where the cards can be sourced from. JM also said the endocrinology team had already sourced some cards for patients they had identified in the pituitary dysfunction clinic.</p>	<p>KMc to circulate via Hot Topics</p> <p>Noted</p>		KMc	11.20	
2020.10.08	Trust Guidelines	<p>Empiric Antibiotic Therapy In Adults A3 "blue person" poster designed for use on wards as an easy format to use of the antibiotic formulary, the poster has already been approved by ACAT and has come to D&T for ratification. AD said this was a useful tool and ask if it could be included in the drug chart as it was easier to follow than the table currently included. JM said she would discuss with ID pharmacist.</p>	Approved	JM to discuss addition to drug chart with ID pharmacist	JM	11.20	
2020.10.09	Minutes SMPC	<p>July 2020 Main issues discussed include Vitamin D prescribing, Policy updates and E prescribing</p>	Noted	No further action			10.20
2020.10.10	Minutes from HERPC	<p>July 2020</p>	Noted	No further action			10.20
2020.10.12	Regional Medicines	<p>None this month – JM informed the committee that RMOC would begin work again this month after a halt in activities due to Covid</p>	Noted	No further action			10.20

	Optimisation Committees						
2020.10.12	Aprotinin Update	Aprotinin Update 2/10/2020 The report showed that there are now only 4 patients with incomplete records and that the trust is now 87% compliant, the NAPaR register target is 80% so this is a great improvement. POB explained that issues with compliance arises as the need for use of Aprotinin is only confirmed once patient is in theatre and therefore all forms are filled in retrospectively.	Noted	No further action			10.20
2020.10.13	Correspondence received	Mr Symes has written to update the committee on the two chairs approvals he had for the use of IV doxycycline to treat seromas. One patient was treated partially successfully and the second procedure was unsuccessful as it was determined the seroma was not the cause of the swelling.	Noted	No further action			10.20
2020.10.14	Chairs approvals	Trametinib- for LGOC as part of COVID19 CDF funding – George Bozas	Noted	No further action			10.20
2020.10.15	Issues to escalate to OQC	DC was not present but AM asked if JM could discuss with him the need for a discussion around the NaPTA about corticosteroids at OQC			JM	11.20	
2020.10.16	Any Other Business	Tinzaparin is only on formulary for use should there be a supply disruption with dalteparin. JM asked if paediatric use could be added as once daily administration of tinzaparin was preferable to twice daily administration of dalteparin in paediatric patients, the committee agreed with this.	WH to update formulary		WH	11.20	
	Date and Time of Next Meeting	Date: Thursday 12th November 2020 Time: 8.15-9.30am Venue: Webex					